ACRO, Drugmakers Request Clearer FDA Guidance on Multiple-Endpoint Trials

Drug Industry Daily
A A
Pharmaceutical companies and clinical research organizations are seeking greater clarity in an FDA draft guidance covering clinical trials with multiple endpoints.

To View This Article:

Login

Subscribe To Drug Industry Daily